Pharming Group Overview

  • Year Founded
  • 1988

Year Founded

  • Status
  • Public

  • Employees
  • 409

Employees

  • Stock Symbol
  • PHARM

Stock Symbol

  • Investments
  • 10

  • Share Price
  • $1.22
  • (As of Thursday Closing)

Pharming Group General Information

Description

Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.

Contact Information

Formerly Known As
GENFARM, Pharming Holding
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • Vondellaan 47
  • 2332 AA Leiden
  • Netherlands
+31 071
Primary Industry
Pharmaceuticals
Other Industries
Other Commercial Services
Drug Discovery
Biotechnology
Stock Exchange
AMS
Vertical(s)
Corporate Office
  • Vondellaan 47
  • 2332 AA Leiden
  • Netherlands
+31 071

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Pharming Group Stock Performance

As of 19-Nov-2026, Pharming Group’s stock price is $1.22. Its current market cap is $866M with 708M shares.

(As of Thursday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.22 $1.23 $0.92 - $2.18 $866M 708M 8.44M $0.04

Pharming Group Financials Summary

As of 30-Sep-2026, Pharming Group has a trailing 12-month revenue of $387M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 667,423 1,131,665 611,307 716,953
Revenue 386,717 376,134 297,200 245,316
EBITDA 46,281 33,529 7,844 6,214
Net Income 24,153 2,851 (11,841) (10,548)
Total Assets 496,637 499,963 399,985 462,854
Total Debt 114,513 115,775 112,313 171,545
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Pharming Group Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Pharming Group‘s full profile, request access.

Request a free trial

Pharming Group Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare di
Pharmaceuticals
Leiden, Netherlands
409 As of 2025

Amsterdam, Netherlands
 

Bangalore, India
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Pharming Group Competitors (44)

One of Pharming Group’s 44 competitors is uniQure, a Formerly VC-backed company based in Amsterdam, Netherlands.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
uniQure Formerly VC-backed Amsterdam, Netherlands
Eurofins Advinus Corporate Backed or Acquired Bangalore, India
Biocon Formerly PE-Backed Bengaluru, India
Evotec Formerly PE-Backed Hamburg, Germany
Takeda Pharmaceutical Corporation Tokyo, Japan
You’re viewing 5 of 44 competitors. Get the full list »

Pharming Group Patents

Pharming Group Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026171834-A1 Pi3k delta inhibitors for use in the treatment of immune dysregulation in common variable immunodeficiency Pending 14-Feb-2025
AU-2024326448-A1 Quinones for use in the treatment of red blood cell enzymopathies Pending 21-Aug-2023
AU-2024329068-A1 Quinones for use in the treatment of red blood cell enzymopathies Pending 21-Aug-2023
EP-4766345-A1 Quinones for use in the treatment of red blood cell enzymopathies Pending 21-Aug-2023
EP-4766346-A1 Quinones for use in the treatment of red blood cell enzymopathies Pending 21-Aug-2023 C07D235/02
To view Pharming Group’s complete patent history, request access »

Pharming Group Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Pharming Group Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Pharming Group‘s full profile, request access.

Request a free trial

Pharming Group Investments & Acquisitions (10)

Pharming Group’s most recent deal was a Secondary Transaction - Private with Abliva for . The deal was made on 18-Jun-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Abliva 18-Jun-2025 Secondary Transaction - Private Drug Discovery
Abliva 14-Feb-2025 Merger/Acquisition Drug Discovery
Pharming Group (EU Commercial Rights) 01-Jan-2020 Corporate Asset Purchase Buildings and Property
Novartis (Leniolisib) 13-Aug-2019 Corporate Asset Purchase Buildings and Property
BioConnection 09-Apr-2019 Corporate BPO/Outsource Services
You’re viewing 5 of 10 investments and acquisitions. Get the full list »

Pharming Group ESG

Risk Overview

Risk Rating

Updated November, 17, 2026

27.74 | Med Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Pharming Group’s complete esg history, request access »

Pharming Group Exits (1)

Pharming Group’s most recent exit was on 23-Mar-2006 from Dnage. The exit was categorized as .

Company Name Exit Date Exit Type Exit Size Status Buyers
Dnage 23-Mar-2006 Completed
To view Pharming Group’s complete exits history, request access »

Pharming Group Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Abliva Lund, Sweden 2000

Pharming Group FAQs

  • When was Pharming Group founded?

    Pharming Group was founded in 1988.

  • Where is Pharming Group headquartered?

    Pharming Group is headquartered in Leiden, Netherlands.

  • What is the size of Pharming Group?

    Pharming Group has 409 total employees.

  • What industry is Pharming Group in?

    Pharming Group’s primary industry is Pharmaceuticals.

  • Is Pharming Group a private or public company?

    Pharming Group is a Public company.

  • What is Pharming Group’s stock symbol?

    The ticker symbol for Pharming Group is PHARM.

  • What is the current stock price of Pharming Group?

    As of 19-Nov-2026 the stock price of Pharming Group is $1.22.

  • What is the current market cap of Pharming Group?

    The current market capitalization of Pharming Group is $866M.

  • What is Pharming Group’s current revenue?

    The trailing twelve month revenue for Pharming Group is $387M.

  • Who are Pharming Group’s competitors?

    uniQure, Eurofins Advinus, Biocon, Evotec, and Takeda Pharmaceutical are some of the 44 competitors of Pharming Group.

  • What is Pharming Group’s annual earnings per share (EPS)?

    Pharming Group’s EPS for 12 months was $0.04.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process